Page 218 - SAMRC Annual Report 2024-2025

Strategic Risk context to Risk Opportunities to
priorities value creation mitigations create value
Support, through Lack of further development and commercialization of (a) SAMRC-owned and (b)
funding and other SAMRC-funded innovations
mechanisms, • IP and Commercialization • Active engagement for
technology Limited funding for/value Policy, Strategy and external partnering to
development and proposition of innovation, Procedures pursue commercialization
implementation, reducing interest from opportunities
and innovations industry to commercialize or • Regular review of the SAMRC
target market to implement
in health and the innovation IP portfolio
technology delivery • Active follow on SAMRC-
to improve health funded projects to progress
to next stage of development
Build human Limited research capacity in scarce skills
capacity for
Further development of • Capacity building strategy for • Continuous engagement
the long-term
research scientists needed supporting the development with Universities to identify
sustainability of
to assist in growing the pool of HDI research scientist scholarship and bursary
the South African
of South African HDI medical candidates
health research
research scientist
• Established strategic
relations with institutions for
collaboration and accessing
researchers to build clinical
research capacity
Translate new Ensuring knowledge translation
knowledge into
The risk of funding invested • SAMRC strategic and • Dedicated on-going
policies and
in interventions not business plans in place investigation for further
practices to
progressing into the next international funding
improve health • Understanding Units
phase of development/ needs and identifying and opportunities
translation leading to sharing success of research
missed opportunity to translation stories
impact nations health/sub-
optimally designed studies
not meeting key stakeholder
requirements

216 SAMRC ANNUAL REPOR T 2024-25